1月30日，阿斯利康CEO苏博科（PascalSoriot）在接受媒体采访时表示，在英国首相斯塔默访华期间公布对华投资的消息意义重大。在世界面临诸多挑战之 际，中英之间建立长期、稳定、战略性的伙伴关系，将有助于应对复杂的国际挑战。 就在前一天，阿斯利康刚刚宣布，计划于2030年前在中国投资超过1000亿元人民币，以扩大在药品生产与研发领域的布局。这也是阿斯利康史上最大规模对 华投资计划。从收入来看，阿斯利康是中国最大的跨国制药公司，中国占该公司收入的约12%。 中英合作前景广阔 苏博科称，八年前，他也曾随同英国首相访华，两国之间拥有巨大的合作潜力。"英国高度重视科学发展，拥有先进的科研体系和顶尖的高等学府。中国同 样注重科学与创新。"他表示。 阿斯利康表示，新的投资计划将增强公司在细胞疗法和放射性配体疗法等前沿技术方面的能力，中国在这些领域的领先地位已得到公认。 公司称，此项投资与"健康中国2030"目标高度契合，并将优先支持中国的共同健康目标实现，着力提升未覆盖人群的疾病预防、早期筛查与创新药物可及 性。 就最新的对华投资项目，阿斯利康表示，将充分发挥中国的科研优势和先进制造能力，依托中英医疗健康生态系统之 ...

Core Viewpoint - Novartis has emerged as a pioneer in the field of targeted radioligand therapy, demonstrating significant clinical results in cancer treatment [2][3] Group 1: Clinical Results and Innovations - Initial clinical trials of Novartis' radioligand therapy showed that approximately 9% of participants had complete cancer cell disappearance, which increased to 21% in subsequent trials [3] - The therapy involves intravenous administration of a solution containing radioactive isotopes attached to ligands that specifically target cancer cell receptors, allowing for precise delivery of radiation [5] - Lutathera, a radioligand therapy drug acquired by Novartis, was first approved in 2017 for certain gastrointestinal cancers, and Pluvicto, a prostate cancer drug, received approval in 2022 with expanded indications [8][14] Group 2: Market Potential - The market for radioligand therapy is estimated to reach $10 billion, with potential growth to $25-30 billion if the therapy meets expectations [8][11] - Novartis is exploring various isotopes and therapy combinations, aiming to expand indications to other cancer types such as lung, breast, pancreatic, and colon cancers [9][11] Group 3: Challenges and Logistics - The production and delivery of radioligand therapy face significant logistical challenges, including the need for rapid production and transportation of radioactive materials to patients within a limited time frame [12][15] - Novartis has been investing in overcoming these challenges, including the use of generative AI to predict logistics issues and the establishment of additional production facilities in China, Japan, and the U.S. [14][16] - The therapy requires specialized facilities for patient isolation due to the retention of radioactive materials in the body, which poses additional infrastructure challenges [15][16] Group 4: Competitive Landscape - Other pharmaceutical companies, including Eli Lilly, AstraZeneca, and Sanofi, are also pursuing opportunities in the radioligand therapy space, indicating a growing competitive market [9] - Novartis has a first-mover advantage with seven potential radioligand therapies in clinical trials and a strong pipeline, setting a high entry barrier for competitors [9][16]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology sector [5][4]. Core Insights - The report highlights the unique advantages of radioligand therapy in targeted treatment and integrated diagnosis, with Xiantong Pharmaceutical expected to become the first "nuclear medicine stock" in Hong Kong [2][11]. - The radioligand drugs are positioned to overcome common resistance seen in other therapies, allowing for seamless transitions from diagnosis to precise treatment, with real-time monitoring of treatment effects [2][12]. - The global radiopharmaceutical market is projected to grow from $9.7 billion in 2024 to $57.3 billion by 2035, with a CAGR of 17.5% [15][12]. Summary by Sections Market Performance - The overall A-share market increased by 1.34%, with the biotechnology sector outperforming at a 3.64% rise [1][40]. - Specific sub-sectors such as chemical pharmaceuticals and biological products saw increases of 5.03% and 4.40%, respectively [1][40]. Company Focus - Xiantong Pharmaceutical has developed a comprehensive and differentiated product pipeline focusing on oncology, neurodegenerative diseases, and cardiovascular diseases, with three products nearing commercialization [2][27]. - The core product XTR005 is the first PET diagnostic radioligand approved in China for AD biomarkers, while XTR008 is positioned as a potential first targeted SSTR therapeutic radioligand in China [2][30]. Financial Projections - Key companies in the sector, such as Mindray Medical and WuXi AppTec, are projected to have significant profit growth, with PE ratios decreasing over the forecast period [4][4]. - Xiantong Pharmaceutical's revenue for 2024 is projected at approximately 440.6 million, with a narrowing net loss of 6.83 million [35][35]. Clinical Development - XTR008 has shown significant efficacy and safety in Phase III trials, with an overall response rate (ORR) of 43.4% compared to 1% in the control group [30][32]. - The company is also advancing multiple candidates in various stages of clinical development, including XTR021 for prostate cancer and XTR006 for neurodegenerative diseases [33][30]. Market Opportunities - The report emphasizes the growing demand for targeted therapies in China, particularly for GEP-NETs and prostate cancer, with market sizes expected to reach approximately $2 billion and $7 billion by 2030, respectively [16][16].